奥麦罗制药 OMER 深 沪
等待开盘 04-01 09:30:00 美东时间
10.56
+0.750
+7.65%
华盛通- 最 高10.62
- 今 开10.00
- 成交量 178.89万股
- 最 低 9.99
- 昨 收 9.81
- 总市值 7.49亿
- 52周最高 17.65
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.95
- 委 比 99.52%
- 总股本 7090.05万
- 历史最高 30.23
- 量 比 2.18
- 振 幅 6.42%
- 历史最低 0.92
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Omeros Q4 Adj. EPS $3.14 Beats $(0.57) Estimate
Omeros (NASDAQ:OMER) reported quarterly earnings of $3.14 per share which beat the analyst consensus estimate of $(0.57) by 650.88 percent. This is a 598.41 percent increase over losses of $(0.63) per share from the same
今天 04:06
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Omeros Q4 2025 Earnings Preview
Omeros (OMER) is scheduled to announce Q4 earnings results on Monday, March 30th, after market close. The consensus EPS Estimate is $0.36 (+166.7% Y/Y) and the consensus Revenue Estimate is $0M Over t...
03-31 05:35
Omeros updates its financial calendar; management hosts a conference call and webcast for FY2025 results
Omeros updates its financial calendar; management hosts a conference call and webcast for FY2025 results Omeros will release financial results for the fourth quarter and year ended Dec. 31, 2025 on March 31, 2026 after market close. A conference call and webcast is scheduled for March 31, 2026 at 4:
03-26 20:45
Omeros to host EBMT industry session on TA-TMA treatment advances
Omeros to host EBMT industry session on TA-TMA treatment advances Omeros will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm to 4pm CET in Madrid. The session is titled “Advances in TA-TMA Treatme
03-21 15:23
Omeros Completes Initial Trial In Nonhuman Primates To Evaluate OncotoX-AML Cancer Therapeutic Platform
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML
02-17 21:46
Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment
Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia (AML). The study demonstrated a marked, selective, and
02-17 21:45
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
02-05 01:35
Omeros higher after first commercial sales of transplant therapy
Shares of Omeros Corporation (OMER) gained on Tuesday after the company announced first commercial shipments of Yartemlea, its recently approved therapy for hematopoietic stem cell transplant-associat...
01-28 01:38
